Related Experiment Video
Updated: May 27, 2026

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
Published on: February 21, 2018
BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas
Qingguo Yan1, Yuanxue Huang, A James Watkins
1Division of Molecular Histopathology, Department of Pathology, University of Cambridge, Cambridge, UK.
Abstract:
The genetics and pathogenesis of splenic marginal zone lymphoma are poorly understood. The lymphoma lacks chromosome translocation, and approximately 30% of cases are featured by 7q deletion, but the gene targeted by the deletion is unknown. A recent study showed inactivation of A20, a "global" NF-κB negative regulator, in 1 of 12 splenic marginal zone lymphomas. To investigate further whether deregulation of the NF-κB pathway plays a role in the pathogenesis of splenic marginal zone lymphoma, we screened several NF-κB regulators for genetic changes by PCR and sequencing. Somatic mutations were found in A20 (6/46=13%), MYD88 (6/46=13%), CARD11 (3/34=8.8%), but not in CD79A, CD79B and ABIN1. Interestingly, these genetic changes are largely mutually exclusive from each other and MYD88 mutation was also mutually exclusive from 7q deletion. These results strongly suggest that deregulation of the TLR (toll like receptor) and BCR (B-cell receptor) signaling pathway may play an important role in the pathogenesis of splenic marginal zone lymphoma.
Insights
Genetic changes in NF-κB regulators like A20 and MYD88 are implicated in splenic marginal zone lymphoma pathogenesis. These mutations suggest the toll-like receptor and B-cell receptor pathways are key in this lymphoma.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- The genetic basis and development of splenic marginal zone lymphoma (SMZL) remain largely unclear.
- While 7q deletion is observed in about 30% of SMZL cases, the specific gene affected is unknown.
- Previous research indicated A20 inactivation in a small subset of SMZL, suggesting potential involvement of the NF-κB pathway.
Purpose of the Study:
- To investigate the role of NF-κB pathway deregulation in the pathogenesis of splenic marginal zone lymphoma.
- To screen key NF-κB regulators for genetic alterations in SMZL.
Main Methods:
- Polymerase Chain Reaction (PCR) and DNA sequencing were employed to screen for somatic mutations.
- Specific NF-κB regulators including A20, MYD88, CARD11, CD79A, CD79B, and ABIN1 were analyzed.
Main Results:
- Somatic mutations were identified in A20 (13%), MYD88 (13%), and CARD11 (8.8%).
- No mutations were found in CD79A, CD79B, or ABIN1.
- The observed genetic alterations, particularly MYD88 mutations, were largely mutually exclusive with each other and with 7q deletion.
Conclusions:
- Deregulation of the toll-like receptor (TLR) and B-cell receptor (BCR) signaling pathways is strongly suggested to be crucial in SMZL pathogenesis.
- Mutations in A20, MYD88, and CARD11 point towards the involvement of these key signaling pathways in the development of splenic marginal zone lymphoma.
Related Concept Videos
Diversity of Antigen Receptors
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
Cells of the Adaptive Immune Response
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
Abnormal Proliferation

